Subscribe
Sign in
Latest
Top
Discussions
Arrowhead and ARO-DIMER-PA (Part III): Reading Early Clinical Studies of Integrated Drugs
A short series on integrated drug design.
Jan 30
•
Thomas Altman
2
2
Arrowhead and ARO-DIMER-PA (Part II): The Case for Integrated Drugs
A short series on integrated drug design
Jan 29
•
Thomas Altman
1
Arrowhead’s ARO-DIMER-PA: From Drugs to Designed Systems
For a long time, drug development has followed a simple pattern. One drug is designed to affect one main biological mechanism.
Jan 28
•
Thomas Altman
3
From “Target X” to Execution-Grade IP
What Arrowhead’s latest TfR1 patent tells us about delivery maturity and platform scope.
Jan 26
•
Thomas Altman
2
Coherence Without Consciousness
AI, Meaning, and the Limits of the Consciousness Debate
Jan 20
•
Thomas Altman
2
Paths Through Uncertainty
RNAi, Gene Editing, and the Long View in Biotech Investing
Jan 14
•
Thomas Altman
3
INHBE, ALK7, and the Next Layer of Obesity Biology
Why This Follow-Up Exists
Jan 7
•
Thomas Altman
2
Understanding Arrowhead’s TRiM Platform
A practical guide to how Arrowhead builds RNAi medicines at scale
Jan 4
•
Thomas Altman
2
December 2025
Arrowhead in 2025: A Year in the Record
It would be easy to frame 2025 as the year Arrowhead filed plozasiran in January and received approval in November.
Dec 30, 2025
•
Thomas Altman
2
Reading the Preclinical ALK7 Data: What Arrowhead Is Actually Testing in Humans
As Arrowhead’s obesity programs move into early human testing, comparisons and expectations have begun to accelerate.
Dec 28, 2025
•
Thomas Altman
2
Reading the Preclinical INHBE Data: What Arrowhead and Wave Are Actually Optimizing For
As INHBE has emerged as a shared target across multiple RNAi obesity programs, comparisons have become almost unavoidable.
Dec 26, 2025
•
Thomas Altman
3
2
Why Obesity Isn’t a Single-Pathway Disease
How to Read Arrowhead’s January Data
Dec 21, 2025
•
Thomas Altman
2
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
